Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study’s senior authors. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were “reeducated” to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.
A History of Scientific Achievements for Cell-Based Therapies
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body’s own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body’s own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.
“Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients,” said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study’s senior authors. “It’s extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up.”
In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.
Results Demonstrate Potential of New Therapy
In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation — the standard of care and the only curative option for B-ALL patients — following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.
The Latest on: Cell therapy
via Google News
The Latest on: Cell therapy
- CAR T-cell therapy may be harnessed to treat heart diseaseon September 11, 2019 at 10:02 am
CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients' own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition ...
- Is treatment forever? Success of gene therapy for inherited blindness depends on timingon September 11, 2019 at 6:57 am
But questions remain about how long-lasting these improvements will be and whether progressive degeneration of vision cells have been halted with the therapy. In a new paper in the journal Molecular ...
- Gyros Protein Technologies launches Gyrolab p24 Kit for scientists in cell and gene therapy marketon September 11, 2019 at 5:53 am
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab ® p24 Kit, for ...
- Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnologyon September 11, 2019 at 4:11 am
BOCA RATON, Fla., Sept. 11, 2019 /PRNewswire/ -- Arcline Investment Management ("Arcline"), a growth oriented private equity firm with $1.5 billion of capital under management, today announced ...
- Michael Schumacher is now 'conscious' after undergoing stem-cell therapy at a Paris hospitalon September 11, 2019 at 3:34 am
Getty Michael Schumacher Michael Schumacher is 'conscious' after being admitted to a Paris hospital for stem-cell treatment on Monday, a report claims. The seven-time Formula One champion was admitted ...
- 2019 Lasker Award Winners: B and T Cell Discoverers, Cancer Therapy Developers, and Gavion September 10, 2019 at 1:08 pm
The Albert and Mary Lasker Foundation today named five researchers and an organization that promotes vaccination of children in underdeveloped countries as winners of its annual awards for work that ...
- Exceed $15 Bn By 2025 |Stem Cell Therapy Market 2019 Set For Massive Growthon September 10, 2019 at 6:29 am
Sep 10, 2019 (AmericaNewsHour) -- Stem Cell Therapymarket report provides a comprehensive landscape of the industry, accurate market estimates and forecast split by product, application, technology, ...
- RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in Chinaon September 10, 2019 at 4:32 am
YOFOTO (China) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials VANCOUVER, Sept.
- BRIEF-Novartis Presents Anticipated Results From Phase III Trial Of B-Cell Therapy Ofatumumabon September 9, 2019 at 10:33 pm
* NOVARTIS WILL PRESENT 34 ABSTRACTS FROM LEADING MS PORTFOLIO, INCLUDING HIGHLY ANTICIPATED RESULTS FROM PHASE III TRIAL OF INVESTIGATIONAL B-CELL THERAPY OFATUMUMAB (OMB157), DATA FOR MAYZENT® ...
- T-cell therapy receives FDA’s orphan drug status for soft tissue sarcomaon September 9, 2019 at 1:45 pm
The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. ADP-A2M4 (Adaptimmune ...
via Bing News